Latest News
The myth of the ‘Asian century’
What is really happening is the rebalancing of the world as European and American hegemony dwindles away
What is really happening is the rebalancing of the world as European and American hegemony dwindles away What is really happening is the rebalancing of the world as European and American hegemony dwindles away Moneycontrol Latest News Read More
What is really happening is the rebalancing of the world as European and American hegemony dwindles away
Venus Remedies gets GMP certification from Ukraine for Carbapenem, oncology facilities in HP
In a statement here, the company said it received certification for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of Carbapenem.
In a statement here, the company said it received certification for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of Carbapenem. In a statement here, the company said it received certification for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of Carbapenem. Moneycontrol Latest News Read More
In a statement here, the company said it received certification for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of Carbapenem.
Venus Remedies share price gains on GMP Certification from Ukraine
The share touched a 52-week high of Rs 263.55 and a 52-week low of Rs 145 on May 31, 2023 and February 8, 2023, respectively.
The share touched a 52-week high of Rs 263.55 and a 52-week low of Rs 145 on May 31, 2023 and February 8, 2023, respectively. The share touched a 52-week high of Rs 263.55 and a 52-week low of Rs 145 on May 31, 2023 and February 8, 2023, respectively. Moneycontrol Latest News Read More
The share touched a 52-week high of Rs 263.55 and a 52-week low of Rs 145 on May 31, 2023 and February 8, 2023, respectively.
Delhivery gains as Macquarie remains bullish on higher volumes
The research house has stuck to its “outperform� rating with target price of Rs 460 a share, saying it sees higher volumes and market share gains
The research house has stuck to its “outperform� rating with target price of Rs 460 a share, saying it sees higher volumes and market share gains The research house has stuck to its “outperform� rating with target price of Rs 460 a share, saying it sees higher volumes and market share gains Moneycontrol Latest News Read More
The research house has stuck to its “outperform� rating with target price of Rs 460 a share, saying it sees higher volumes and market share gains
Online bond platforms coming together to form an industry association
With the aim of organising themselves into an industry association, several online bond platforms got together on June 6 to hold preliminary discussions on forming such an entity.
With the aim of organising themselves into an industry association, several online bond platforms got together on June 6 to hold preliminary discussions on forming such an entity. With the aim of organising themselves into an industry association, several online bond platforms got together on June 6 to hold preliminary discussions on forming such an entity. Moneycontrol Latest News Read More
With the aim of organising themselves into an industry association, several online bond platforms got together on June 6 to hold preliminary discussions on forming such an entity.
English 
हिन्दी